The operating system for precision medicine 2.0

One comprehensive platform that offers biopharma speed, scale, and integrated solutions for all lifecycle stages.

8.5M+de-identified research records

450+petabytes of unique data elements per patient on average

5K+connected healthcare institutions

5M+cancer patients covered by the TIME network

Research

Help de-risk and accelerate the path to clinic

Clinical Research

Boost confidence at each developmental milestone

Commercialization

Understand and take action on real-world experience

Explore our customer success stories to see why Tempus is a trusted partner for 95% of the top 20 pharma companies* and more than 250 biopharma companies.

Our impact

Cancer drug discovery and clinical development are being transformed by the ability to analyze vast amounts of rich data using artificial intelligence.

—Jorge Reis-Filho, Chief AI and Data Scientist, Oncology R&D, AstraZeneca

The collaboration with Tempus positions Merck to advance our precision oncology strategy through the application of the latest AI/ML capabilities to discover novel precision biomarkers, identify mechanisms of cancer cell resistance, and inform rational combinations for drugs in our early pipeline.

—George Addona, Senior Vice President, Discovery, Preclinical Development and Translational Medicine, Merck Research Laboratories

By combining internal, pre-clinical experimental data, with real-world data from Tempus on its AI-powered platform, we can profoundly deepen our understanding of cancer biology and accelerate our drug discovery and development efforts.

—Mark Paul Petronczki, Head of Oncology Research, Boehringer Ingelheim

Collaborating with Tempus to evaluate KRAS mutation status using the xT assay was an important component of the RAMP-201 clinical trial. Continuing our collaboration to fully develop a CDx assay is part of our post-marketing commitment to the FDA for our recent accelerated approval of avutometinib plus defactinib and is a critical step in bringing targeted therapies to patients with recurrent KRAS-mutant LGSOC.

—John Hayslip, MD, Chief Medical Officer, Verastem Oncology

Featured resources

Article

Blurred circular light reflections create an abstract pattern on a dark, textured background.

Beyond the EHR: Building a reliable mortality endpoint for oncology research

Explore how Tempus’ validated, composite mortality endpoint overcomes data fragmentation to provide a trustworthy foundation for RWE.

Article

Blurred indoor scene with an overlay of glowing blue and purple alphanumeric code.

Building the engine to scale data abstraction through AI

Learn how Tempus’ AI engine transforms unstructured clinical text into analysis-ready RWD. Tempus AI leaders detail the multi-layered system that ensures speed, scale, and fidelity.

Webinar

Ask a scientist: How to leverage novel datasets to answer complex research questions

Discover how Tempus helps researchers use specialized data to answer complex research questions, and how analysis-ready datasets can accelerate discovery and power new hypotheses in IO.

Article

Abstract blurred digital background with glowing blue and white data patterns.

How real-world data drives value and de-risks development

Explore how RWD helps bridge the gap from preclinical research to clinical validation, addresses evolving regulatory demands, and provides the evidence needed to build confidence with investors and partners.

Article

Abstract digital background with repeating letters M, P, E, T forming a matrix pattern.

A new data-driven playbook for improving ADC success rates

Discover Tempus’ data-driven playbook that leverages multimodal RWD, AI, and patient-derived models to de-risk the ADC lifecycle and improve success rates.

Webinar

A new era of biopharma R&D: The TechBio revolution—realities and the next frontier

Tempus and Recursion leaders discuss their strategic TechBio partnership and how they use AI and supercomputing with petabytes of data to accelerate drug discovery and development.

Case Study

Document showing 'Indication selection and biomarker strategy' with a pie chart illustrating target prevalence.

Validating a novel target and informing trial design for a first-in-class therapeutic

Discover how a biopharma company used Tempus’ de-identified multimodal data to support validation of a novel target and inform trial design for a first-in-class therapeutic.

Article

$Grid of 'T' characters on light gray with iridescent effects and rainbow light refraction.$

Q&A: Using RWD to bridge discovery and development in translational research

Learn how Tempus leverages real-world data, AI, and systems biology to accelerate drug discovery and development.

White Paper

Precision Medicine 2.0: The operating system for oncology R&D

Gain a comprehensive overview of Precision Medicine 2.0, its core scientific pillars, enabling technologies, and how R&D organizations can leverage this integrated approach to optimize their cancer research.

Explore by solution

Data & AI →

Companion Diagnostics & Lab Services →

Clinical Trial Recruitment →

Clinical Research Organization Services →

Care Gap Intelligence →

This is AI-enabled precision medicine

This is the future of healthcare.

The operating system for precision medicine 2.0

Research

Clinical Research

Commercialization

Explore our customer success stories to see why Tempus is a trusted partner for 95% of the top 20 pharma companies* and more than 250 biopharma companies.

AstraZeneca

Mirati Therapeutics

Recursion

Pfizer

Sermonix

Bristol Myers Squibb

BioNTech

GSK

Eisai

Stemline Therapeutics, Inc.

MD Anderson Cancer Center

JW Pharmaceutical

Takeda

Remix Therapeutics

United Therapeutics

IFLI

TScan

Aadi Bioscience

AstraZeneca

Gilead

AstraZeneca

Kronos Bio

AstraZeneca

Actuate Therapeutics

Gilead

Sermonix

A2 Bio

AstraZeneca and Pfizer

TScan

GSK

Janssen

GSK

Kartos Therapeutics

Eli Lilly

Geisinger

Genmab

Janssen

AstraZeneca

Kronos Bio

Bristol Myers Squibb

Genmab

Kronos

Our impact

Featured resources

Beyond the EHR: Building a reliable mortality endpoint for oncology research

Building the engine to scale data abstraction through AI

Ask a scientist: How to leverage novel datasets to answer complex research questions

How real-world data drives value and de-risks development

A new data-driven playbook for improving ADC success rates

A new era of biopharma R&D: The TechBio revolution—realities and the next frontier

Validating a novel target and informing trial design for a first-in-class therapeutic

Q&A: Using RWD to bridge discovery and development in translational research

Precision Medicine 2.0: The operating system for oncology R&D

Explore by solution

This is AI-enabled precision medicine